Compass Therapeutics (NASDAQ:CMPX) Lowered to Market Perform Rating by Leerink Partners

Compass Therapeutics (NASDAQ:CMPX) was downgraded by investment analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, Marketbeat reports. They currently have a $4.00 target price on the stock, down from their previous target price of $5.00. Leerink Partners’ price objective indicates a potential upside of 151.57% from the stock’s current price.

CMPX has been the subject of a number of other reports. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Monday. Finally, LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Monday, September 16th.

Compass Therapeutics Trading Down 5.9 %

Shares of CMPX stock opened at $1.59 on Friday. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.34. The stock has a market capitalization of $218.77 million, a P/E ratio of -4.30 and a beta of 0.92. The firm’s 50 day moving average is $1.76 and its 200 day moving average is $1.42.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. As a group, equities analysts predict that Compass Therapeutics will post -0.42 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. SG Americas Securities LLC lifted its holdings in Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after purchasing an additional 5,515 shares in the last quarter. Rhumbline Advisers raised its position in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares during the period. Rovin Capital UT ADV purchased a new position in shares of Compass Therapeutics during the 3rd quarter valued at $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth $30,000. Finally, Bank of New York Mellon Corp increased its stake in Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock worth $284,000 after buying an additional 31,433 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.